<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Wingard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H20422799"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Invasive fungal infections are common in selected hematopoietic cell transplant (HCT) recipients, such as allogeneic HCT recipients during the pre-engraftment period and in those with severe graft-versus-host disease and cause substantial morbidity and mortality.</p><p>Interest in antifungal prophylaxis for high-risk HCT recipients has been prompted by the rising incidence of life-threatening invasive fungal infections in such patients, the difficulty in establishing the diagnosis early in the course of infection, and the recognition that treatment outcomes are poor if initiation of therapy is delayed.</p><p>The epidemiology and prophylaxis of invasive fungal infections in HCT recipients will be discussed here. The epidemiology and prophylaxis of invasive fungal infections in patients with hematologic malignancies is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies"</a>.)</p><p>Other important issues related to infections in HCT recipients are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15674.html" rel="external">"Treatment and prevention of Fusarium infection"</a>.)</p><p></p><p class="headingAnchor" id="H20422806"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Both yeasts and molds cause serious invasive fungal infections in HCT recipients  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). Prior to the routine use of antifungal prophylaxis, <em>Candida</em> spp accounted for the majority of fungal infections that occurred during the pre-engraftment period of HCT, followed by <em>Aspergillus</em> spp. More recently, <em>Aspergillus</em> has surpassed <em>Candida</em> as a cause of invasive fungal infections in HCT recipients, associated with the use of effective antifungal prophylaxis targeting <em>Candida</em> spp [<a href="#rid1">1</a>]. Both pathogens are associated with substantial risk for mortality.</p><p class="headingAnchor" id="H20422813"><span class="h2">Candida infection</span><span class="headingEndMark"> — </span><em>Candida</em> is the most important yeast pathogen in HCT recipients, accounting for most invasive yeast infections [<a href="#rid1">1-3</a>]. Meta-analyses and randomized trials have determined that the threshold incidence of <em>Candida</em> infection for which <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis appears to be efficacious is 6 to 10 percent [<a href="#rid4">4-7</a>]. Infection rates at or above this threshold are seen primarily during the pre-engraftment phase in allogeneic HCT recipients receiving myeloablative conditioning regimens and in some autologous HCT recipients who are not given prophylactic hematopoietic growth factors or who are at risk for severe oral and/or gastrointestinal mucositis (which is a risk factor for candidemia) [<a href="#rid8">8</a>].</p><p>Although <em>Candida</em> is ordinarily a harmless colonizer of mucosal surfaces and skin, breeches in skin or mucosal integrity can lead to invasion of deep tissues and hematogenous dissemination. The portal of entry for this commensal organism is thought to be primarily the gastrointestinal tract in this patient population, with translocation occurring as a result of mucosal injury from cytotoxic chemotherapy and total body irradiation given in the pretransplant conditioning regimen.</p><p>Candidemia is the most frequent clinical manifestation of invasive candidiasis. <em>Candida</em> is also a common fungal cause of central venous catheter infections. Less commonly, <em>Candida</em> causes disseminated candidiasis, including chronic disseminated candidiasis (hepatosplenic candidiasis). HCT recipients are at highest risk for invasive candidiasis during the pre-engraftment period  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). Prior to the routine use of antifungal prophylaxis, the rate of invasive <em>Candida</em> infections was approximately 16 to 18 percent [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a>.)</p><p>Although <em>C. albicans</em> accounts for about one-half of invasive <em>Candida</em> infections, HCT recipients are also at increased risk for infections caused by non-albicans <em>Candida</em> species (eg, <em>C. glabrata</em>, <em>C. tropicalis</em>) compared with other types of patients [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis", section on 'Prevalence of Candida species'</a>.)</p><p class="headingAnchor" id="H20422820"><span class="h2">Aspergillus infection</span><span class="headingEndMark"> — </span><em>Aspergillus</em> is the most common mold pathogen, occurring most commonly during the post-engraftment period in patients with severe graft-versus-host disease [<a href="#rid12">12-15</a>]. Among allogeneic HCT recipients, the incidence of invasive aspergillosis ranges from 4 to 24 percent, with most studies reporting rates between 8 and 15 percent; in contrast, the incidence of invasive aspergillosis is only 1 to 2 percent among autologous HCT recipients [<a href="#rid16">16</a>].</p><p>The usual portal of entry of this airborne organism is inhalation into the sinuses and respiratory tract. The most frequent manifestation of invasive aspergillosis is pneumonia. Pulmonary infiltrates due to <em>Aspergillus</em> typically consist of one or more nodules with or without surrounding ground-glass opacities (the halo sign), cavities, air-crescent signs, or focal airspace consolidation. Other manifestations include sinusitis, localized skin ulcers, subcutaneous nodules, cerebral infarction, and/or fulminant disseminated disease.</p><p><em>A. fumigatus</em> is the most common <em>Aspergillus</em> species to cause disease, but several other <em>Aspergillus</em> species also cause invasive disease. (See  <a class="medical medical_review" href="/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H20422827"><span class="h2">Other fungal infections</span><span class="headingEndMark"> — </span>The agents of mucormycosis are the second most common cause of mold infections in HCT recipients [<a href="#rid17">17,18</a>] but are infrequent overall at most centers [<a href="#rid19">19,20</a>]. Mucormycosis can cause life-threatening rhino-orbital, pulmonary, cerebral, and/or disseminated infection [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)", section on 'Risk factors'</a>.)</p><p><em>Fusarium</em> spp and <em>Scedosporium</em> spp have also been reported in HCT recipients. (See  <a class="medical medical_review" href="/d/html/2426.html" rel="external">"Mycology, pathogenesis, and epidemiology of Fusarium infection"</a> and  <a class="medical medical_review" href="/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a>.)</p><p>Although primary infection and reactivation infection with endemic fungi (histoplasmosis, blastomycosis, and coccidioidomycosis) is uncommon in HCT recipients, these fungi should also be considered in patients with prolonged glucocorticoid use or other immunosuppression who have lived in or traveled to endemic areas. (See  <a class="medical medical_review" href="/d/html/2450.html" rel="external">"Pathogenesis and clinical features of pulmonary histoplasmosis"</a> and  <a class="medical medical_review" href="/d/html/2458.html" rel="external">"Mycology, pathogenesis, and epidemiology of blastomycosis"</a> and  <a class="medical medical_review" href="/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a>.)</p><p><em>Pneumocystis jirovecii </em>historically has been a frequent cause of pneumonia. With routine anti-<em>Pneumocystis</em> prophylaxis, <em>Pneumocystis</em> pneumonia occurs infrequently today. However, <em>Pneumocystis</em> infections can occasionally occur; the risk is influenced by lapses in adherence to the prophylactic regimen and may be more frequent with certain prophylactic agents. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p class="headingAnchor" id="H20422834"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for invasive fungal infections in HCT recipients are discussed below.</p><p class="headingAnchor" id="H20422848"><span class="h2">Allogeneic HCT</span><span class="headingEndMark"> — </span>After allogeneic HCT, there are three periods of elevated risk for invasive fungal infection  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>) [<a href="#rid14">14,22,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>During the neutropenic pre-engraftment phase</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During the early post-engraftment period, especially in patients who develop graft-versus-host disease (GVHD) requiring glucocorticoids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During the late post-engraftment period, in patients who develop severe chronic GVHD that requires prolonged high-dose glucocorticoids or patients who relapse and must undergo reinduction chemotherapy.</p><p></p><p>Prior to engraftment, most fungal infections are due to <em>Candida</em> spp and the risk for invasive aspergillosis is low, except in patients with prior <em>Aspergillus</em> infections or in patients who have prolonged neutropenia due to delay in or failure of engraftment. Risk factors for invasive candidiasis during the pre-engraftment period include neutropenia, severe mucositis, and central venous catheter use [<a href="#rid24">24</a>]. Risk factors for aspergillosis before engraftment include prior multiple chemotherapy regimens, iron overload from multiple erythrocyte transfusions, prior history of invasive aspergillosis, failure to engraft after transplantation, and delayed engraftment such as is occasionally seen with umbilical cord blood transplantation [<a href="#rid14">14,25</a>]. Patients with advanced or refractory acute myelogenous leukemia are at higher risk of invasive mold infections than other leukemia patients. (See  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Acute leukemia'</a>.)</p><p>After engraftment, the risk for invasive aspergillosis is much greater. Risk factors for <em>Aspergillus</em> infection after engraftment are GVHD and prolonged courses of glucocorticoids at high doses (&gt;1 mg/kg per day of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> or the equivalent dose of another glucocorticoid) [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H20422855"><span class="h2">Autologous HCT</span><span class="headingEndMark"> — </span>The risk for invasive fungal infections is lower in autologous HCT recipients than allogeneic HCT recipients, but invasive fungal infections do occur in such patients. Risk factors for <em>Candida</em> infections in autologous HCT recipients include intensive conditioning regimens that cause substantial mucosal injury (resulting in oral and/or gastrointestinal mucositis), as well as prolonged neutropenia [<a href="#rid26">26</a>]. Autologous HCT recipients at risk for prolonged neutropenia include those who received a suboptimal number of stem cells and those who did not receive myeloid growth factors following transplantation. Autologous HCT recipients are not usually at high risk for invasive aspergillosis or other mold infections, unless they have a prior history of such an infection.</p><p class="headingAnchor" id="H20422869"><span class="h1">PROPHYLAXIS</span></p><p class="headingAnchor" id="H20422877"><span class="h2">Primary prophylaxis</span><span class="headingEndMark"> — </span>Primary prophylaxis involves the administration of an antimicrobial agent to prevent infection in patients at increased risk who have not previously had the type of infection being targeted. The benefits of primary antifungal prophylaxis have been demonstrated in multiple studies. Much of the emphasis historically has been on the prevention of <em>Candida</em> infections. However, studies of <em>Aspergillus</em> prevention have intensified in recent years.</p><p>A 2007 meta-analysis that included 64 randomized trials compared systemic antifungal prophylaxis (eg, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>) with a control arm (placebo, no intervention, or a nonsystemic antifungal agent such as <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a>) in cancer patients receiving myelosuppressive chemotherapy (predominantly for acute leukemia) or undergoing HCT [<a href="#rid4">4</a>]. The following findings were observed in HCT recipients:</p><p class="bulletIndent1"><span class="glyph">●</span>In allogeneic HCT recipients, antifungal prophylaxis reduced all-cause mortality (relative risk [RR] 0.62, 95% CI 0.45-0.85), fungal-related mortality (RR 0.52, 95% CI 0.27-0.99), and the incidence of documented invasive fungal infection (RR 0.33, 95% CI 0.18-0.63).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In autologous HCT recipients, patients who received antifungal prophylaxis with low-dose intravenous (IV) amphotericin B had similar effect estimates as allogeneic HCT patients, but there were only a few studies, and sample sizes were small and lacked the power to reach significance. Changes in practices, including a multitude of new conditioning regimens, routine use of myeloid growth factors, and greater numbers of stem cells in peripheral blood grafts, means that the risk of fungal infections with current autologous transplant regimens is not clear and the efficacy of antifungal prophylaxis in patients receiving these regimens has not been studied sufficiently. Thus, the applicability of findings in prior studies is uncertain.</p><p></p><p>A 2012 meta-analysis that included 20 randomized trials compared mold-active prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis in HCT recipients (14 trials) or patients with hematologic malignancy receiving chemotherapy (6 trials) with the following results [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis reduced the number of proven or probable invasive fungal infections compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis (RR 0.71, 95% CI 0.52-0.98).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis reduced the risk of invasive aspergillosis compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis (RR 0.53, 95% CI 0.37-0.75).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis reduced the risk of invasive fungal infection-related mortality compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis (RR 0.67, 95% CI 0.47-0.96).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in overall mortality between patients who received mold-active prophylaxis and those who received <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis was associated with an increased risk of adverse events leading to antifungal discontinuation (RR 1.95, 95% CI 1.24-3.07).</p><p></p><p>It is important to note that most of the apparent benefit to anti-mold prophylaxis was observed in the non-HCT patients and that most large trials of HCT recipients have not shown a convincing benefit for anti-mold prophylaxis over <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>.</p><p class="headingAnchor" id="H3281131920"><span class="h3">Approach to primary prophylaxis</span><span class="headingEndMark"> — </span>The following recommendations represent our approach to antifungal prophylaxis in HCT recipients. These recommendations are generally in keeping with the 2018 American Society of Clinical Oncology and Infectious Diseases Society of America (IDSA) antimicrobial prophylaxis guidelines for patients with cancer-related immunosuppression [<a href="#rid8">8</a>], the 2016 IDSA guidelines for the diagnosis and management of aspergillosis [<a href="#rid28">28</a>], and the 2009 international guidelines for preventing infectious complications in HCT recipients [<a href="#rid24">24</a>].</p><p>It should be noted that there is ongoing controversy about the use of antifungal prophylaxis (see  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Risk-benefit assessment'</a>). In addition, the need for antifungal prophylaxis depends at least in part upon local rates of resistance as well as the overall risk of invasive fungal infections based upon which HCT regimens are used. As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution.</p><p>We favor the following approach to primary antifungal prophylaxis in HCT recipients:</p><p class="bulletIndent1"><span class="glyph">●</span>For recipients of myeloablative allogeneic HCT who do not have one of the indications for mold prophylaxis discussed below, we recommend prophylaxis against <em>Candida</em> infections during the pre-engraftment period with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg orally once daily) [<a href="#rid24">24</a>]. A fluconazole dose of 200 mg once daily has also been studied [<a href="#rid29">29</a>], but we prefer the 400 mg daily dose out of a theoretical concern that the lower dose could promote the development of resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For autologous HCT recipients who receive conditioning regimens that are expected to cause severe mucositis during the pre-engraftment period (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus either ablative doses of <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> or total body irradiation), we suggest prophylaxis against <em>Candida</em> infections with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg orally once daily) [<a href="#rid8">8,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who undergo myeloablative allogeneic HCT for acute myelogenous leukemia, we suggest anti-mold prophylaxis [<a href="#rid19">19,21</a>]. When mold prophylaxis is indicated in an HCT recipient, we generally favor <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (200 mg orally twice daily), but <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is an appropriate alternative. When posaconazole is chosen, we prefer the delayed-release tablet (taken with food) rather than the oral suspension. Another alternative for anti-mold prophylaxis if neither voriconazole nor posaconazole can be given is <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, although it has not been studied for this indication in randomized controlled trials.</p><p></p><p class="bulletIndent1">Patients who are unable to take medications orally or who are expected not to absorb oral medications can be given IV <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>. Posaconazole delayed-release tablets should be given as a loading dose of 300 mg (three 100 mg tablets) every 12 hours on the first day, followed by a maintenance dose of 300 mg (three 100 mg tablets) daily starting on the second day. The IV formulation of posaconazole should be given as a loading dose of 300 mg every 12 hours on the first day, followed by a maintenance dose of 300 mg daily starting on the second day. The dosing of the oral suspension of posaconazole is 200 mg three times daily. The delayed-release tablets, the IV formulation, and the oral suspension should <strong>not</strong> be used interchangeably due to differences in dosing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the association between prolonged neutropenia and invasive aspergillosis, we also suggest prophylaxis during the pre-engraftment period with a mold-active agent in the subset of HCT recipients with a lengthy duration of neutropenia immediately prior to HCT (eg, patients with aplastic anemia) and for those who are anticipated to have slow engraftment (&gt;28 days; eg, umbilical cord blood transplant recipients) or who fail to engraft. In such patients, we generally favor <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (200 mg orally twice daily), but <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is an appropriate alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As there are many potential drug interactions between extended-spectrum triazoles and drugs that may be used concomitantly, drug interactions should be taken into account before starting a triazole. (See <a class="local">'Drug interactions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For allogeneic HCT recipients with GVHD requiring <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> at a dose of ≥1 mg/kg per day (or the equivalent dose of another glucocorticoid) for longer than three weeks, we recommend anti-mold prophylaxis. We favor <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> in such patients, but <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is an appropriate alternative. The same precautions regarding drug interactions that are discussed above must be considered.</p><p></p><p class="headingAnchor" id="H20422884"><span class="h3">Candida infection</span><span class="headingEndMark"> — </span>Randomized placebo-controlled trials have shown that <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> reduces the incidence of invasive <em>Candida</em> infections during the pre-engraftment period following allogeneic HCT [<a href="#rid9">9,10</a>]. In one of these trials, HCT recipients who received fluconazole had a lower risk of invasive fungal infections (3 versus 16 percent) and fungal infection-related mortality (0.6 versus 5.6 percent) but not all-cause mortality [<a href="#rid9">9</a>]. In another trial, HCT recipients who received fluconazole until day 75 following transplantation had a lower risk of invasive fungal infections (7 versus 18 percent) as well as both fungal infection-related mortality (7 versus 13 percent) and all-cause mortality (20 versus 35 percent) [<a href="#rid10">10</a>]. In a follow-up study in which patients were followed for eight years following HCT, a continued mortality benefit was observed in the patients who received fluconazole (23 versus 45 percent) [<a href="#rid30">30</a>]. Fewer patients who received fluconazole died with invasive candidiasis either early (before day 110; 0.7 versus 9 percent) or late (after day 110; 0.8 versus 8 percent).</p><p>Meta-analyses and randomized trials have determined that <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is efficacious in preventing <em>Candida</em> infections in high-risk patients [<a href="#rid4">4-7</a>]. Infection rates at or above a threshold of 10 percent are seen primarily in the following groups of HCT recipients during the pre-engraftment phase [<a href="#rid8">8,24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Allogeneic HCT recipients receiving myeloablative conditioning regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some autologous HCT recipients who are not given prophylactic hematopoietic growth factors or who are at risk for severe oral and/or gastrointestinal mucositis (which is a risk factor for candidemia) – The transplant regimens best known to cause substantial mucosal injury are <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus either ablative doses of <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> or total body irradiation. There is a growing list of transplant preparative regimens with varying degree of intensity that have been insufficiently studied with respect to their effects on mucosal integrity, and thus the risk of <em>Candida</em> infection is not well characterized in patients receiving these regimens.</p><p></p><p class="headingAnchor" id="H20422891"><span class="h4">Choice of agent</span><span class="headingEndMark"> — </span>When <em>Candida</em> prophylaxis is indicated, we favor <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. Fluconazole has the advantage of being available as oral and IV formulations, excellent tolerability, inexpensive generic formulations, and less severe interactions with concomitant medications compared with the extended-spectrum azoles. Although fluconazole has been studied most rigorously for <em>Candida</em> prophylaxis, other agents have also been evaluated and are considered acceptable alternatives, including <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, and <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> [<a href="#rid8">8</a>].</p><p><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> has several important drawbacks, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Its spectrum of activity against <em>Candida</em> spp is narrower than the echinocandins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breakthrough infections with fluconazole-resistant <em>Candida</em> species, especially <em>C. krusei</em> and <em>C. glabrata</em>, have been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It has no activity against <em>Aspergillus</em> or other molds in comparison with the other acceptable agents, which have at least some activity against <em>Aspergillus</em> spp.</p><p></p><p>Alternative agents have the following benefits and drawbacks:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echinocandins</strong> – The echinocandins (<a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>, and <a class="drug drug_general" data-topicid="141155" href="/d/drug information/141155.html" rel="external">rezafungin</a>) have a broader spectrum of activity than <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, with most common <em>Candida</em> species being susceptible, and an excellent safety record. Drawbacks are their availability only as intravenous formulations and high cost. There has been a growing concern about the emergence of echinocandin resistance among <em>Candida</em> spp (see  <a class="medical medical_review" href="/d/html/13945.html" rel="external">"Pharmacology of echinocandins and other glucan synthesis inhibitors"</a>) [<a href="#rid31">31</a>]. Rezafungin has been approved for the treatment of candidemia and systemic candidiasis [<a href="#rid32">32</a>]. A prophylaxis trial is underway in allogeneic HCT recipients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> – Voriconazole has both oral and IV formulations but has been noted to cause transient visual disturbances (that are not permanent or serious), perhaps more liver toxicity than <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, and some variability in blood levels in allogeneic HCT recipients. A major drawback is its potential interactions with certain chemotherapy agents. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">Posaconazole</a> – Posaconazole was previously available only as an oral suspension. In 2013, delayed-release tablets became available and, in 2014, an IV formulation became available. Posaconazole has been evaluated primarily for its anti-mold activity, but in trials low rates of <em>Candida</em> infections were noted, and it is therefore an option for prevention of yeast infections [<a href="#rid33">33</a>]. We prefer the delayed-release tablet over the oral suspension because it has more reliable oral absorption and achieves higher blood levels [<a href="#rid34">34,35</a>]. A drawback is its potential interactions with certain chemotherapy agents. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Posaconazole'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Posaconazole'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> – Itraconazole is available as an oral formulation. The IV formulation has been withdrawn in the United States but remains available in some countries. The oral formulation is poorly tolerated and has variable bioavailability. Another major drawback is its potential interactions with certain chemotherapy agents. Itraconazole is used rarely given these limitations. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">Isavuconazole</a> – Isavuconazole is available in intravenous and oral formulations. It is indicated for the treatment of invasive aspergillosis and invasive mucormycosis. Its safety profile has encouraged investigators to use this agent, off-label, as prophylaxis [<a href="#rid36">36</a>]. A retrospective study suggested higher rates of breakthrough invasive fungal infections in HCT and hematologic malignancy patients with isavuconazole prophylaxis compared with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> prophylaxis [<a href="#rid37">37</a>]. However, a recent multicenter prospective observational registry study examined breakthrough invasive fungal infections (bIFI) among high-risk patients receiving mold-active prophylaxis with posaconazole, voriconazole, isavuconazole, or multiple sequenced mold-active triazoles. Haematological malignancy was the underlying diagnosis in the majority (76.5 percent) of enrollees. bIFI were observed in 11 of 221 (5 percent) isavuconazole recipients, 20 of 374 (5.3 percent) posaconazole recipients, 9 of 226 (4 percent) voriconazole recipients, and 33 of 209 (15.8 percent) multiple-sequenced mold-active triazoles. Discontinuation of mold-active triazoles due to adverse drug reactions occurred in 5 of 245 (2 percent) of isavuconazole recipients, in 30 of 368 (8.2 percent) of posaconazole recipients, and in 27of 267 (10.1 percent) voriconazole recipients, 64 of 262 (24.4 percent) multiple sequenced mold-active triazole recipients. These real-world observations suggest that isavuconazole may be as effective and safe as posaconazole or voriconazole for mold-active anti-fungal prophylaxis.</p><p></p><p>Each of the agents used for antifungal prophylaxis is associated with some risk of hepatotoxicity, but azoles are likely to confer the highest risk. For patients with significant hepatic dysfunction (eg, hepatic sinusoidal obstruction syndrome [veno-occlusive disease]), we favor an echinocandin over an azole.</p><p class="headingAnchor" id="H20422898"><span class="h3">Aspergillus (and other mold) infection</span><span class="headingEndMark"> — </span>The need for <em>Aspergillus</em> prophylaxis varies according to the underlying disease and its therapy. Several trials suggest that the risk-benefit ratio favors prophylaxis when the rate of invasive aspergillosis is at least 6 percent [<a href="#rid33">33,38</a>]. A meta-analysis that compared mold-active prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis is discussed above [<a href="#rid27">27</a>]. (See <a class="local">'Primary prophylaxis'</a> above.)</p><p><em>Aspergillus</em> prophylaxis with <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> has been demonstrated to be beneficial in patients with severe graft-versus-host disease (GVHD) following HCT [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H20422944"><span class="h4">Allogeneic HCT recipients</span><span class="headingEndMark"> — </span>As noted above, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is effective at reducing rates of invasive <em>Candida</em> infection in allogeneic HCT recipients, but it lacks anti-mold activity. Agents with anti-mold activity include <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, and amphotericin B; all of these agents also have activity against <em>Candida</em> spp. During the pre-engraftment period, <em>Candida</em> is the fungal pathogen of greatest concern in the majority of patients, and fluconazole is therefore adequate for prophylaxis early after HCT in most patients. However, allogeneic HCT recipients are also at some risk for mold infections during the pre-engraftment period and are at the highest risk during the post-engraftment phase in the setting of severe GVHD. The use of antifungal agents with activity against <em>Aspergillus</em> and other molds has been evaluated in various studies of HCT recipients, both during the pre-engraftment period and later in patients with severe GVHD.</p><p class="headingAnchor" id="H232631507"><span class="h5">Prophylaxis during the pre-engraftment period</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> prophylaxis have been studied most extensively in allogeneic HCT recipients during the pre-engraftment period and, compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, appear to modestly reduce the incidence of invasive fungal infections without conferring a survival benefit. Relevant findings from trials include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> was compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (with both agents being given until day 100 after HCT) in a randomized double-blind trial conducted in 600 allogeneic HCT recipients [<a href="#rid19">19</a>]. Among patients who received voriconazole versus fluconazole, fungal-free survival (the primary endpoint, defined as freedom from an invasive fungal infection or death at 180 days) was similar (78 versus 75 percent). There were trends toward fewer invasive fungal infections (7 versus 11 percent), <em>Aspergillus</em> infections (9 versus 17), and less frequent use of empiric antifungal therapy (24 versus 30 percent) in patients who received voriconazole compared with those who received fluconazole. In a post-hoc subgroup analysis of HCT recipients who were transplanted for acute myelogenous leukemia, those who received voriconazole had significantly improved fungal-free survival (78 versus 61 percent) and fewer invasive fungal infections (8.5 versus 21 percent), but no difference in overall survival (81 versus 72 percent) compared with those who received fluconazole.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were observed in a randomized open-label trial comparing <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> with <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> in 489 patients undergoing allogeneic HCT [<a href="#rid39">39</a>]. In patients who received voriconazole versus itraconazole, there were no differences in the incidence of proven or probable invasive fungal infections (1.3 versus 2.1 percent) or survival to day 180 (82 versus 81 percent). There were fewer interruptions of study drug with voriconazole. Gastrointestinal adverse effects were more common with itraconazole, but there were more adverse visual and hepatic effects with voriconazole.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> has been compared with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> in randomized trials using the IV formulation and the oral suspension [<a href="#rid40">40,41</a>]. One small trial found fewer fungal infections but no survival benefit [<a href="#rid40">40</a>], whereas another trial showed a trend toward inferior survival and was stopped prematurely due to greater toxicity associated with concomitant administration of itraconazole and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> compared with fluconazole and cyclophosphamide and considerable intolerance of itraconazole [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose IV <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> has been evaluated for the prophylaxis of invasive fungal infections in patients undergoing HCT, with conflicting results [<a href="#rid42">42</a>]. The toxicities of amphotericin B deoxycholate make it unsuitable for use after HCT. Several trials have evaluated lipid formulations of amphotericin B, which are less toxic than amphotericin B deoxycholate, but the efficacy results have been mixed [<a href="#rid43">43-46</a>]. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Safety and efficacy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">Posaconazole</a> and <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a> have not been well studied during the pre-engraftment period of HCT [<a href="#rid37">37,47,48</a>]. However, one retrospective review of 145 patients with hematologic malignancies and HCT recipients suggests that isavuconazole may be less effective than both <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> and posaconazole [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H232631515"><span class="h5">Prophylaxis in patients with GVHD</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">Posaconazole</a> has been evaluated in the post-engraftment period in patients with graft-versus-host disease (GVHD) requiring high-dose glucocorticoid therapy [<a href="#rid38">38</a>]. In a randomized double-blind trial, 600 allogeneic HCT patients with GVHD were assigned to posaconazole (200 mg three times daily of the oral suspension) or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg once daily) for prophylaxis of invasive fungal infections [<a href="#rid38">38</a>]. Patients were eligible for the trial if they had grade II to IV acute GVHD or if they had chronic extensive GVHD or if they were being treated with intensive immunosuppressive therapy (≥1 mg/kg per day of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> or the equivalent dose of another glucocorticoid; or antithymocyte globulin; or a combination of two or more immunosuppressive agents) (see  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>). At the end of the 112-day treatment period, posaconazole was associated with a trend toward fewer proven and probable invasive fungal infections (5.3 versus 9.0 percent; odds ratio [OR] 0.56, 95% CI 0.30-1.07) and a significant reduction in proven or probable invasive aspergillosis (2.3 versus 7.0 percent; OR 0.31, 95% CI 0.13-0.75), which accounted for the majority of infections.</p><p>Although there were no significant differences in the overall incidence of invasive fungal infections between the patients receiving <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, significantly fewer patients receiving posaconazole developed breakthrough invasive fungal infections (2.4 versus 7.6 percent), particularly invasive aspergillosis (1.0 versus 5.9 percent) [<a href="#rid38">38</a>]. Mortality from invasive fungal infections was also significantly lower in the posaconazole group (1 versus 4 percent). Treatment-related adverse events were similar in both groups. Some patients (7 percent in the posaconazole group, 10 percent in the fluconazole group) had positive galactomannan assays before enrollment into the trial and thus may have had incipient <em>Aspergillus</em> infections. This raises the possibility that some patients were receiving treatment for established infections rather than prophylaxis and suggests that the putative benefit of posaconazole as prophylaxis is less than suggested in the report.</p><p>Because of the uncertainty of the benefit of anti-mold prophylaxis in this situation, practices vary considerably from center to center. Some centers give no anti-mold prophylaxis or give <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis while maintaining vigilance for <em>Aspergillus</em> infections with laboratory screening (eg, <em>Aspergillus</em> galactomannan antigen, beta-D-glucan) and/or early diagnostic tests for patients with suggestive findings (eg, <em>Aspergillus</em> galactomannan antigen, beta-D-glucan, computed tomography [CT] scans). Other centers use <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> prophylaxis in all patients with GVHD requiring high-dose glucocorticoid therapy. Still other centers give anti-mold prophylaxis with either voriconazole or posaconazole in patients who require doses of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> of at least 1 mg/kg per day (or the equivalent dose of another glucocorticoid) for longer than three weeks, drawing on the observation that those patients who require prolonged high-dose glucocorticoids are at greatest risk [<a href="#rid23">23</a>]. <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> is limited by poor tolerability and unreliable absorption [<a href="#rid28">28</a>]. We use voriconazole prophylaxis for patients with GVHD requiring methylprednisolone of at least 1 mg/kg per day (or the equivalent dose of another glucocorticoid) for longer than three weeks. Patients requiring high doses of glucocorticoids are generally those with more severe (grade II to IV) GVHD.</p><p class="headingAnchor" id="H20422951"><span class="h4">Autologous HCT recipients</span><span class="headingEndMark"> — </span>Autologous HCT recipients do not require primary prophylaxis against <em>Aspergillus</em> spp and other molds, given the low rate of such infections in these patients. (See <a class="local">'Aspergillus infection'</a> above.)</p><p class="headingAnchor" id="H20422958"><span class="h4">Choice of agent</span><span class="headingEndMark"> — </span>Current data are insufficient to conclusively determine which mold-active drug is optimal for prophylaxis. The choice of the initial antifungal agent may vary based on an institution's experience (ie, epidemiology and susceptibility patterns), risk for specific mold infections (eg, <em>Aspergillus</em> versus the agents of mucormycosis), and patient category (acute myelogenous leukemia [AML] induction therapy versus HCT). In general, most experts prefer <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> if <em>Aspergillus</em> is the most likely pathogen for which one has concern (eg, prior infection with <em>Aspergillus</em>, epidemiology at that center, patient population). Voriconazole has been studied more extensively after HCT, whereas <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> has been studied more extensively in AML patients receiving induction therapy. Some experts recommend either voriconazole or posaconazole based on the published literature. But, as mentioned above, there are specific strengths and drawbacks to each agent (see <a class="local">'Choice of agent'</a> above). When the decision is made that anti-mold prophylaxis is justified in an HCT recipient, we generally recommend voriconazole.</p><p>In patients at increased risk for mucormycosis, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> should be given since <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> has no activity against the agents of mucormycosis. However, it is important to note that, at most centers, aspergillosis accounts for the majority of invasive mold infections. As an example, in a multicenter surveillance study of HCT recipients in the United States, 363 invasive mold infections were detected within the first year following HCT; aspergillosis was diagnosed in 66 percent of cases whereas mucormycosis was diagnosed in 12 percent [<a href="#rid1">1</a>]. Among HCT recipients, the reported incidence of mucormycosis has ranged from 0.1 to 2 percent, with the highest incidence in patients with GVHD [<a href="#rid49">49</a>].</p><p>When <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is given, we prefer the delayed-release tablet (taken with food) over the oral suspension due to its better absorption [<a href="#rid34">34,35</a>]. This is especially important for patients who cannot eat a full meal; the delayed-release tablets result in higher plasma drug concentrations than the oral suspension regardless of food intake [<a href="#rid50">50</a>]. Patients who are unable to take medications orally or who are expected not to absorb oral medications should be given IV posaconazole. </p><p>Another alternative for patients who cannot receive <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, although it has not been studied for prophylaxis in randomized controlled trials. </p><p>As there are many potential drug interactions between the extended-spectrum triazoles and drugs that may be used concomitantly, drug interactions should be taken into account before starting a triazole. (See <a class="local">'Drug interactions'</a> below.)</p><p>Because of inter-patient variability in drug levels of the mold-active azoles, therapeutic drug monitoring should be done when possible [<a href="#rid28">28</a>]. Serum trough drug levels for the mold-active azoles as well as for potentially interacting drugs, such as the calcineurin inhibitors and other CYP3A4 substrates, are advised. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p class="headingAnchor" id="H20422965"><span class="h3">Risk-benefit assessment</span><span class="headingEndMark"> — </span>Although antifungal prophylaxis has been proven to be efficacious in allogeneic HCT recipients, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the heterogeneity of risk and the overall relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify individuals at increased risk for invasive fungal infections. The level of immunosuppression is higher following allogeneic HCT compared with other settings, such as following consolidation chemotherapy for leukemia. Important comorbidities include older age, mucositis, poorly controlled diabetes, smoking history, iron overload from transfusions, and recurrent use of antibacterial agents.</p><p>Factors that support the use of antifungal prophylaxis in high-risk patients include the substantial morbidity and mortality of invasive fungal infections and the difficulty in obtaining a timely diagnosis due to the limitations of available diagnostic tests [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H20422993"><span class="h2">Secondary prophylaxis</span><span class="headingEndMark"> — </span>Patients who have a history of a prior invasive fungal infection, especially <em>Aspergillus</em> infection, are at high risk for recurrence of infection following HCT. This has been best studied in patients with prior <em>Aspergillus</em> infection. In the past, prior mold infection was deemed a contraindication for HCT due to the high risk of recurrent infection and death. However, more recently, it has been shown that continued treatment after initial control (so-called secondary prophylaxis) can prevent reactivation of infection in most patients and permit HCT [<a href="#rid51">51,52</a>].</p><p>For patients with a history of prior invasive aspergillosis undergoing allogeneic or autologous HCT and for patients with a prolonged period of neutropenia immediately prior to HCT, we recommend antifungal prophylaxis with a mold-active agent [<a href="#rid53">53</a>]. The choice of agent depends in part upon the need to avoid drug interactions while chemotherapy is being given. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> is the first-line agent for <em>Aspergillus</em> spp and has been best studied as secondary prophylaxis, but mold-active azoles are usually not given concomitantly with certain chemotherapy regimens with hepatically metabolized drugs. Of note, this is not a concern for agents such as <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> or <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>. (See <a class="local">'Approach to primary prophylaxis'</a> above and <a class="local">'Drug interactions'</a> below and  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Approach to primary prophylaxis'</a>.)</p><p>For patients with prior <em>Candida</em> infections, the agent selected for secondary prophylaxis should be based upon the <em>Candida</em> species and which agent was successful in achieving earlier control.</p><p class="headingAnchor" id="H20423000"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of antifungal prophylaxis should be individualized based on the patient's clinical status and history of prior fungal infections. The following general principles can be used to help determine the appropriate duration of prophylaxis:</p><p class="bulletIndent1"><span class="glyph">●</span>In allogeneic HCT recipients who do not have GVHD, prophylaxis against <em>Candida</em> spp is continued either until engraftment or for up to 75 days following transplantation, which in one trial was associated with continued benefit after engraftment [<a href="#rid10">10,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal duration of antifungal prophylaxis in allogeneic HCT recipients with GVHD has not been defined [<a href="#rid24">24</a>]. In general, prophylaxis should be continued during the period of peak immunosuppression (eg, glucocorticoid equivalent of ≥1 mg/kg per day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for more than two weeks or addition of other anti-GVHD therapies for refractory GVHD) [<a href="#rid28">28</a>]. In such patients, we continue anti-mold prophylaxis until substantial doses of immunosuppressants (especially glucocorticoids) are no longer required. As an example, we suggest stopping once the dose of prednisone drops below 20 mg every other day, but the optimal duration has not been formally studied. The use of CD4 counts to guide when to stop antifungal prophylaxis (eg, &gt;200 cells/L) has been found to be useful in some immunocompromised patient groups, but this has not been well studied in HCT patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have a history of a prior invasive fungal infection who are receiving secondary prophylaxis following HCT, prophylaxis is usually continued until discontinuation of immunosuppressive therapy. In such patients, follow-up imaging (CT scan of the organ involved in prior infection) and fungal markers (eg, <em>Aspergillus</em> galactomannan antigen, beta-D-glucan) are often obtained two to four weeks after antifungal prophylaxis has been discontinued to ensure that reactivation has not occurred.</p><p></p><p class="headingAnchor" id="H20423007"><span class="h1">PRE-EMPTIVE THERAPY</span><span class="headingEndMark"> — </span>An alternative to anti-mold prophylaxis involves pre-emptive therapy. This approach involves targeted screening of high-risk patients for markers of colonization and/or infection in an attempt to prevent invasive infection. Screening involves checking fungal markers, such as the <em>Aspergillus</em> galactomannan antigen, <em>Aspergillus</em> polymerase chain reaction (if available), and beta-D-glucan, and chest computed tomography scanning. This approach is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Pre-emptive therapy'</a>.)</p><p class="headingAnchor" id="H20423014"><span class="h1">BREAKTHROUGH INFECTIONS AND RESISTANCE</span><span class="headingEndMark"> — </span>Breakthrough fungal infections and resistance are discussed separately. (See  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Breakthrough infections and resistance'</a>.)</p><p class="headingAnchor" id="H20423021"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>There are many potential drug interactions between antifungal agents and drugs that may be used concomitantly [<a href="#rid54">54</a>]. Specific drug interactions unique to patients with hematologic malignancies and HCT recipients are mentioned here. <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> used in combination with the calcineurin inhibitor class of immunosuppressive drugs (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>) used after HCT is associated with a high risk for severe nephrotoxicity [<a href="#rid55">55</a>]. The risk of nephrotoxicity is much lower with the lipid formulations of amphotericin B.</p><p>The triazoles are metabolized by the cytochrome P450 isoenzymes, and there are multiple potential drug interactions:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> has been associated with a harmful interaction with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, resulting in renal and hepatic toxicity [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">Itraconazole</a> has a potential negative inotropic effect and should be avoided in patients with prior congestive heart failure and drugs that could be cardiotoxic (eg, anthracyclines or high-dose <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interactions between the anti-mold azoles and immunosuppressive drugs are substantial; reductions of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> doses by approximately 50 percent are important, and monitoring of levels of these drugs is necessary to avoid toxicity. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> increases <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> levels by approximately 10-fold [<a href="#rid57">57,58</a>], and <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> increases sirolimus levels by approximately ninefold [<a href="#rid50">50</a>]. The concomitant use of voriconazole or posaconazole with sirolimus is generally avoided. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Selected clinical effects'</a>.)</p><p></p><p>Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (<a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>) prophylaxis should be delayed until after completion of the transplant conditioning regimen. In patients receiving posttransplant <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (eg, haploidentical HCT recipients), extended-spectrum azoles should be avoided until completion of cyclophosphamide. An echinocandin can be given safely if a gap in antifungal prophylaxis is inadvisable, such as in patients with prior aspergillosis. Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes.</p><p>Although drug-drug interactions related to cytochrome P450 metabolism appear less for <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a> than for <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, therapeutic drug monitoring of concomitantly administered drugs metabolized by cytochrome P450 may be prudent.</p><p>Combination prophylaxis with fluoroquinolones and triazoles is common, and both classes have the potential to prolong the QTc interval and increase the risk for torsades de pointes. Other examples of important drug interactions between azoles and other drugs are provided in the table  (<a class="graphic graphic_table graphicRef66477" href="/d/graphic/66477.html" rel="external">table 1</a>). Drug interactions involving azoles are discussed in greater detail separately. Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p>A discussion of the interactions between antifungal agents and chemotherapy drugs is presented separately. (See  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies", section on 'Drug interactions'</a>.)</p><p class="headingAnchor" id="H3478773592"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104073.html" rel="external">"Society guideline links: Invasive fungal infections"</a>.)</p><p class="headingAnchor" id="H20423028"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology and timing of fungal infection</strong> – Both yeasts and molds cause serious invasive fungal infections in hematopoietic cell transplant (HCT) recipients. Prior to the routine use of antifungal prophylaxis, <em>Candida</em> spp accounted for the majority of fungal infections that occurred during the pre-engraftment period of HCT, followed by <em>Aspergillus</em> spp. HCT recipients are at highest risk for <em>Candida</em> infections during the pre-engraftment period  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). <em>Aspergillus</em> is the most common mold pathogen and the second most common fungal pathogen in HCT recipients, occurring most commonly during the post-engraftment period in patients with severe graft-versus-host disease (GVHD). (See <a class="local">'Introduction'</a> above and <a class="local">'Candida infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to prophylaxis</strong> – The following recommendations represent our approach to antifungal prophylaxis. It should be noted that there is ongoing controversy about the use of antifungal prophylaxis. As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution. (See <a class="local">'Approach to primary prophylaxis'</a> above and <a class="local">'Risk-benefit assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks and benefits</strong> – Although antifungal prophylaxis has been proven to be efficacious in selected HCT recipients, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify those individuals at increased risk for invasive fungal infections. (See <a class="local">'Risk-benefit assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic regimens</strong> – We provide antifungal prophylaxis to the following groups of HCT recipients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recipients of myeloablative allogeneic HCT who do not have an indication for mold prophylaxis</strong> – For these patients, we recommend prophylaxis against <em>Candida</em> infections during the pre-engraftment period rather than no prophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In such patients, we use <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg once daily). (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recipients of autologous HCT who receive conditioning regimens that are expected to cause severe mucositis during the pre-engraftment period (eg, </strong><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a><strong> plus either ablative doses of </strong><a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a><strong> or total body irradiation)</strong> – We suggest prophylaxis against <em>Candida</em> infections rather than no prophylaxis for these patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). In such patients, we use <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg once daily). (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recipients of myeloablative allogeneic HCT for acute myelogenous leukemia</strong> – We suggest anti-mold prophylaxis rather than narrower anti-<em>Candida</em> prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). When mold prophylaxis is indicated in an HCT recipient, we generally favor <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (200 mg orally twice daily), but <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is an appropriate alternative. Another alternative for patients who cannot receive voriconazole or posaconazole is <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, although it has not been prospectively studied for prophylaxis. (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who have a lengthy duration of neutropenia immediately prior to HCT (eg, patients with aplastic anemia), are anticipated to have slow engraftment (&gt;28 days; eg, umbilical cord blood transplant recipients), or who fail to engraft</strong> – We suggest prophylaxis during the pre-engraftment period for these patients with an agent that has both anti-mold and anti-<em>Candida</em> activity rather than narrower anti-<em>Candida</em> prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). In such patients, we generally favor <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (200 mg orally twice daily), but <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is an appropriate alternative. Another alternative for patients who cannot receive voriconazole or posaconazole may be <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>. (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recipients of allogeneic HCT who have GVHD requiring </strong><a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a><strong> at a dose of ≥1 mg/kg per day (or the equivalent dose of another glucocorticoid) for longer than three weeks</strong> – We recommend anti-mold prophylaxis rather than no antifungal prophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We favor <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (200 mg orally twice daily) in such patients, but delayed-release <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> is an appropriate alternative. The same precautions regarding drug interactions that are discussed above must be considered. (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HCT recipients who have a history of prior invasive aspergillosis</strong> – For these patients, we recommend antifungal prophylaxis with a mold-active agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Secondary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions and timing of prophylaxis</strong> – Given the potential for serious drug interactions, administration of extended-spectrum triazole-based (<a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>) prophylaxis should be delayed until after completion of the transplant conditioning regimen; an echinocandin can be given safely during the conditioning regimen if a gap in antifungal coverage is unadvisable, such as in a patient with prior aspergillosis. Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. Interactions between the anti-mold azoles and immunosuppressive drugs are substantial; reductions of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> doses by 50 percent are important, and monitoring of levels of these drugs is necessary to avoid toxicity. Coadministration with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> should be avoided due to extreme potentiation of sirolimus levels. (See <a class="local">'Approach to primary prophylaxis'</a> above and <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="headingAnchor" id="H813221772"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.</a></li><li><a class="nounderline abstract_t">Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112:2493.</a></li><li><a class="nounderline abstract_t">Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis 2015; 61:324.</a></li><li><a class="nounderline abstract_t">Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25:5471.</a></li><li><a class="nounderline abstract_t">Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89:1611.</a></li><li><a class="nounderline abstract_t">Bow EJ, Laverdière M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230.</a></li><li><a class="nounderline abstract_t">Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331.</a></li><li><a class="nounderline abstract_t">Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 2018; 36:3043.</a></li><li><a class="nounderline abstract_t">Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.</a></li><li><a class="nounderline abstract_t">Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545.</a></li><li><a class="nounderline abstract_t">Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.</a></li><li><a class="nounderline abstract_t">Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005; 17:89.</a></li><li><a class="nounderline abstract_t">Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am 2011; 25:101.</a></li><li><a class="nounderline abstract_t">Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009; 168:299.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851.</a></li><li><a class="nounderline abstract_t">Wingard JR. Zygomycosis: epidemiology and treatment options. Proceedings of Johns Hopkins Advanced Studies in Medicine 2006; 6:S526.</a></li><li><a class="nounderline abstract_t">Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111.</a></li><li><a class="nounderline abstract_t">Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17:1855.</a></li><li><a class="nounderline abstract_t">Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607.</a></li><li><a class="nounderline abstract_t">Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257.</a></li><li><a class="nounderline abstract_t">Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15.</a></li><li><a class="nounderline abstract_t">Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</a></li><li><a class="nounderline abstract_t">Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5:55.</a></li><li class="breakAll">Norkin M, Wingard JR. Invasive fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. In: Stem Cells in Clinic and Research, Gholamrezanezhad A (Ed), InTech, Rijeka 2011. p.657.</li><li><a class="nounderline abstract_t">Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012; 106:1626.</a></li><li><a class="nounderline abstract_t">Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.</a></li><li><a class="nounderline abstract_t">MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112:369.</a></li><li><a class="nounderline abstract_t">Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055.</a></li><li><a class="nounderline abstract_t">Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis 2015; 61 Suppl 6:S612.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023; 401:49.</a></li><li><a class="nounderline abstract_t">Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.</a></li><li><a class="nounderline abstract_t">Cumpston A, Caddell R, Shillingburg A, et al. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother 2015; 59:4424.</a></li><li><a class="nounderline abstract_t">Kersemaekers WM, Dogterom P, Xu J, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother 2015; 59:3385.</a></li><li><a class="nounderline abstract_t">Villalobos AP, Bow EJ. Isavuconazole as an alternative for antifungal prophylaxis in patients with hematological malignancies: Is the signal sufficient to support clinical practice? Transpl Infect Dis 2023; 25:e14046.</a></li><li><a class="nounderline abstract_t">Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clin Infect Dis 2020; 70:723.</a></li><li><a class="nounderline abstract_t">Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.</a></li><li><a class="nounderline abstract_t">Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155:318.</a></li><li><a class="nounderline abstract_t">Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138:705.</a></li><li><a class="nounderline abstract_t">Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527.</a></li><li><a class="nounderline abstract_t">Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97:509.</a></li><li><a class="nounderline abstract_t">Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23:163.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135.</a></li><li><a class="nounderline abstract_t">Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17:1306.</a></li><li><a class="nounderline abstract_t">Tollemar J, Ringdén O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:577.</a></li><li><a class="nounderline abstract_t">Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 2018; 67:1610.</a></li><li><a class="nounderline abstract_t">Hassouna H, Athans V, Brizendine KD. Real-world use-Isavuconazole at a large academic medical center. Mycoses 2019; 62:534.</a></li><li><a class="nounderline abstract_t">Lanternier F, Sun HY, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54:1629.</a></li><li class="breakAll">Noxafil (posaconazole) injection for intravenous use, delayed-release tablets for oral use, oral suspension, prescribing information. https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf (Accessed on March 18, 2014).</li><li><a class="nounderline abstract_t">Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Rovira M, Maertens J, et al. Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica 2011; 96:e9.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53:95.</a></li><li><a class="nounderline abstract_t">Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29:1402.</a></li><li><a class="nounderline abstract_t">Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557.</a></li><li><a class="nounderline abstract_t">Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552.</a></li><li class="breakAll">Vfend (voriconazole) for oral use, for oral suspension, for injection, for intravenous use, prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=618 (Accessed on November 12, 2008).</li></ol></div><div id="topicVersionRevision">Topic 16534 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218877" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412153" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870323" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909198" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013378" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115356" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064252" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30179565" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542320" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769290" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727637" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Importance of Candida species other than C. albicans as pathogens in oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393425" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880955" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15725910" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The changing face of invasive fungal infections in hematopoietic cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21236393" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247798" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852735" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Zygomycosis in the 1990s in a tertiary-care cancer center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Zygomycosis: epidemiology and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826719" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000355" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14624113" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466269" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11840139" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371357" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fungal infections after bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371357" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fungal infections after bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22568999" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904111" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979947" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567278" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Echinocandin Resistance in Candida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36442484" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251531" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987632" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25824210" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36864665" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Isavuconazole as an alternative for antifungal prophylaxis in patients with hematological malignancies: Is the signal sufficient to support clinical practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30958538" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251530" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880032" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729424" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14525770" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985709" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197802" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162375" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16766594" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8136741" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771293" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30851214" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Real-world use-Isavuconazole at a large academic medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431807" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mucormycosis in organ and stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431807" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mucormycosis in organ and stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034546" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282716" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002883" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinically relevant drug interactions of current antifungal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585786" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504090" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cyclophosphamide metabolism is affected by azole antifungals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635790" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
